ArticleJournal of nanobiotechnology2026
Dual-targeted hybrid nanovesicles coordinated bone-muscle regeneration via regulating the DUSP4/p38 MAPK pathway to reverse osteosarcopenia.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- Mesenchymal stem cells and derived extracellular vesicles in major respiratory diseases: from multifaceted molecular mechanisms to clinical perspectives.Frontiers in cell and developmental biology · 2026Review
- Mesenchymal stem cells-derived extracellular vesicles as a novel drug delivery carrier: engineering strategies and clinical safety estimation.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Osteosarcopenia (OSP), a degenerative syndrome characterized by concurrent osteoporosis and sarcopenia, exhibits persistently high global prevalence due to aging and disuse, yet lacks targeted therapies. p38 MAPK plays a key regulatory role in musculoskeletal degeneration. Increased expression of DUSP4, a key inhibitor of the Mitogen-Activated Protein Kinase (MAPK) pathway, inhibits the phosphorylation of p38 MAPK. Thus, targeted delivery of microRNAs that inhibit DUSP4 expression can activate the p38 MAPK pathway and promote osteogenic and myogenic differentiation. However, the therapeutic efficacy of nucleic acid drugs critically depends on delivery systems with targeted specificity, stability, and biocompatibility. Therefore, we engineered a hybrid nanovesicle (miR@DT/iMNV) by fusing bone-muscle dual-targeting peptide-modified liposomes (miR@DT-Lipo) and iPSC-derived MSC-EVs (iMSC-EVs). The miR@DT/iMNV enables the dual-tissue targeted delivery of miR-206-5p (which is downregulated in OSP and can target and inhibit DUSP4) and exhibits excellent biocompatibility. Results demonstrated that miR@DT/iMNV enhances osteogenic/myogenic capacities of stem cells, modulates macrophage phenotypes, restores mitochondrial function, and increases bone/muscle mass in a disused OSP murine model. This dual-targeted, multi-mechanistic strategy presents an innovative therapeutic approach for OSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.